IPSEN Shares Climb 2.09% at Close, Extending Weekly Rebound
The biopharmaceutical group's stock closed higher, showing strong performance in contrast to a more measured market. While the CAC 40 dropped by 0.19%, Ipsen stood out with its weekly accumulated gains. This momentum is rooted in the third-quarter results announced a week ago, which prompted the company to raise its outlook for the full year 2025.
Ipsen Strengthens Its Position
Ipsen consolidated its positions at 122.00 euros at the close of the session on October 29, strengthening by 2.09% from 119.50 euros the previous day. Over the week, the stock has risen by 7.87%, accumulating a gain of 8.83% over three months. On an annual perspective, the stock has seen a rise of 6.27% since the start of the year, slightly outperforming the CAC 40's twelve-month increase of 8.52%. This movement contrasts with the general direction of the Paris Stock Exchange, which fell by 0.19% in the same session. However, trading occurred on a particularly low volume, with only 0.05% of the capital changing hands. This reduced volume highlights the technical and unspectacular nature of this slight rebound. Nevertheless, this progression is part of a positive trend that began following the publication of the group's results. The stock is now well above its medium and long-term moving averages. The 50-day moving average stands at 116.46 euros, while the 200-day average is at 109.13 euros. The price of 122.00 euros is also above the 121.80 euros level, which has long been a resistance point for the stock for several weeks.
Third Quarter Results Trigger Rebound
The third-quarter results, published on October 22, triggered a marked rebound in the stock with an initial rise of 5.31%. On this occasion, the company announced performances deemed satisfactory for the past quarter, justifying an enhancement of its outlook for the entirety of 2025. This announcement reshuffled the cards for the stock, which was experiencing a period of hesitation prior to this date. The biopharmaceutical context remains favorable for the group: the revised upward outlook reflects activity in line with objectives and sustained commercial dynamics. The announcement effect gradually solidified over the following days. The stock, which was trading around 119.10 euros on October 22, gradually climbed beyond the psychological threshold of 121.80 euros before settling above it at the end of the month. The observed dynamics represent a resurgence of market operators' confidence in the French biopharmaceutical group. Ipsen, which enjoys a market capitalization of approximately 9.83 billion euros, continues to benefit from a valuation deemed reasonable in light of its earnings prospects. The forward price/earnings ratio for 2025 stands at 13.8 times, and 14.3 times for 2026, multiples that are within the industry average.
Technical Perspective on Ipsen
From a technical standpoint, Ipsen displays mixed trend indicators. The Relative Strength Index (RSI) is at 56, placing the stock in a neutral zone, without any excess of overbuying or overselling. The MACD, the moving average convergence/divergence indicator, shows a line at 0.91 with a signal line at 0.25, a positive gap indicating a confirmed bullish dynamic. The Bollinger Bands frame the stock with an upper threshold at 121.76 euros and a lower threshold at 111.62 euros, with the price slightly above the high threshold. The major technical support remains set at 111.50 euros, while the main resistance remains at 121.80 euros, which the stock has now surpassed.
